PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models
about
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsChimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG miceAdoptive T-Cell Therapy for Solid Tumors.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseEnhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.Synthetic immunology: T-cell engineering and adoptive immunotherapy
P2860
Q33761755-35F78D35-68E8-436B-8DAD-6DBB54ACCC7CQ33833475-E6FB2BC9-1D4E-40EC-B17E-EAB2D61DE388Q35980893-B65E6D72-72C8-4B2B-99A3-869F655E7FA2Q36939199-C051D86D-E638-4D85-9EF6-0A1C59ABE593Q37609801-898FD24B-4632-4B19-A054-0F6BDC5C89F0Q37705993-BFA71FC9-871E-4522-90B0-98F6B1958178Q38754498-9F5E80CB-3D43-45BE-897D-05E7AB8C2329Q38831232-1209022A-086D-46DC-ACEC-D72482954CE9Q38874911-0CCAB587-A561-43FA-9A1F-DD7C6E9F6736Q47629566-C530F7A3-5669-4E21-B60B-90E1DD0E5396Q49280922-95343F44-EF29-413E-88BF-468444B99AD1Q55258890-B8651825-2554-474D-A054-919C5A721ABEQ57823195-990F7923-7489-4CE7-A60B-FAE213063612
P2860
PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@ast
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@en
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@nl
type
label
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@ast
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@en
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@nl
prefLabel
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@ast
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@en
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@nl
P2093
P2860
P50
P3181
P1433
P1476
PSMA-specific CAR-engineered T ...... e cancer in preclinical models
@en
P2093
Anna Merlo
Marco Colombatti
Maria Rondina
Sara Bobisse
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0109427
P407
P50
P577
2014-01-01T00:00:00Z